Art. -Nr.: HY-15746A

Dobutamine

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Dobutamine is a synthetic catecholamine that acts on α1-AR, β1-AR, β2-AR (α-1, β-1 andβ-2 adrenoceptors). Dobutamine is a selective β1-AR agonist, relatively weak activity at α1-AR and β2-AR. Dobutamine can increase cardiac output and correct hypoperfusion.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.75%
CAS. Nr.: 34368-04-2
Formel: C₁₈H₂₃NO₃
Molecular Weight:301.38

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Dobutamine Chemical Structure

CAS. Nr.: 34368-04-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vivo
- Clinical Trial
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

α adrenergic receptor

β adrenergic receptor

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HEK293	IC₅₀	4.17 μM Compound: Dobutamine	Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay Inhibition of human OCT1 expressed in HEK293 cells assessed as decrease in uptake of ASP+ after 2 mins by fluorescence assay	[PMID: 28230985]
Hepatocyte	IC₅₀	3.7 nM Compound: Dobutamine	Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs Antimicrobial activity against Plasmodium yoelii 265 liver infected in mammalian hepatocytes after 48 hrs	[PMID: 18212104]

In Vivo

Dobutamine has a rapid onset of action and a short half-life ^[2].
Dobutamine (0.15-20 mg/kg; i.p.) results in subsequent increase in the left ventricular function and heart rate acceleration with an increasing dose in wildtype mice^[3].
Dobutamine results in significant inotropic, lusitropic, and chronotropic cardiac response with a high dose in wildtype mice^[3].
Low doses of Dobutamine significantly increases inotropic and lusitropic cardiac performance without chronotropic changes in the Tgαq*44 mice^[3].
Dobutamine increases heart rate only after high doses, but then inotropic and lusitropic cardiac functional reserve is lost^[3].
Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Tgαq*44 mice (heart failure models)^[3]
Dosage:

0.15 mg/kg, 0.5 mg/kg as a low dose, 1.5 mg/kg, 5 mg/kg, 20 mg/kg as a high dose
Administration:

Intraperitoneal injection
Result:

Induced different response in cardiac function on a low and high dose in mice with with heart failure.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 34368-04-2
Appearance Solid
Molecular Weight 301.38
Formel C₁₈H₂₃NO₃
Color White to off-white
SMILES

OC1=CC=C(CCNC(C)CCC2=CC=C(O)C=C2)C=C1O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (5)

All Apoptosis AnalysisFlow CytometryCell Proliferation/Viability AssayIFWB

Sort by:

Journal Impact Factor

Anal Chem

Open Digital Reference Materials Unchain Controlled Substance Analysis. [Abstract]

2025 Jul 15;97(27):14220-14229. PMID: 40601392
Biochem Pharmacol

Nuciferine suppresses adipogenesis and mitochondrial function in brown adipocytes. [Abstract]

2025 Nov 29:244:117576. PMID: 41319924
Front Cell Dev Biol

The Apoptotic Resistance of BRCA1-Deficient Ovarian Cancer Cells is Mediated by cAMP. [Abstract]

2022 Apr 20;10:889656. PMID: 35517499

Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]

Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) decreased IR-induced cell apoptosis. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-downcells with IR treatment.

Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]

Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) decreased IR-induced cell apoptosis. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-down cells with IR treatment.

Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]

Dobutamine hydrochloride (dobutamine; 10 μM; 18 h; 10 Gy IR) showed the percentages of G1 cells in IRtreated control and BRCA1 knock-down A2780 cells decreased to 44.32 and 43.03%, respectively, suggesting that cAMP terminated the cell cycle arrest caused by DNA damage. Ⅰ: control cells without IR treatment, Ⅱ: control cells with IR treatment, Ⅲ: dobutamine pre-treated control cells with IR treatment, Ⅳ: BRCA1 knock-down cells with IR treatment, Ⅴ: dobutamine pre-treated BRCA1 knock-down cells with IR treatment, Ⅵ: 8-CPT-cAMP pre-treated BRCA1 knock-down cells with IR treatment.

Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]

Dobutamine hydrochloride (dobutamine; 10 μM) treated BRCA1 knock-down A2780 cells could inhibited the proliferation of the CD8+ T cells.

Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]

Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) showed weaker BAX signals in the IR-irradiated control and BRCA1 knockdown A2780 cells, and 13.7 and 14.5% of cancer cells were BAX positive, respectively.

Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]

Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) decreased the protein expression of BAX and cleaved caspase-3 in the IR-irradiated control and BRCA1 knockdown A2780 cells.

Dobutamine purchased from MedChemExpress. Usage Cited in: Front Cell Dev Biol. 2022 Apr 20;10:889656. [Abstract]

Dobutamine hydrochloride (dobutamine; 10 μM; 18 h after IR) decreased the protein expression of p53 in the IR-irradiated BRCA1 knockdown A2780 cells.
Comput Struct Biotechnol J

Drug repurposing screens to identify potential drugs for chronic kidney disease by targeting prostaglandin E2 receptor. [Abstract]

2023 Jul 7:21:3490-3502. PMID: 37484490
Environ Toxicol

Phenylacetyl glutamine (PAGln) enhances cardiomyocyte death after myocardial infarction through β1 adrenergic receptor. [Abstract]

2024 Mar;39(3):1682-1699. PMID: 38041472

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (331.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.3181 mL

16.5904 mL

33.1807 mL

5 mM

0.6636 mL

3.3181 mL

6.6361 mL

10 mM

0.3318 mL

1.6590 mL

3.3181 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 5 mg/mL (16.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 5 mg/mL (16.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 5 mg/mL (16.59 mM); Clear solution

This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (272 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tuttle RR, et al. Dobutamine: development of a new catecholamine to selectively increase cardiac contractility. Circ Res. 1975 Jan;36(1):185-96. [Content Brief]

[2]. Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris). 1991 Jun;40(6):397-402. [Content Brief]

[3]. Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37(3):669-77. [Content Brief]

[4]. Tibayan FA, et al. Dobutamine increases alveolar liquid clearance in ventilated rats by beta-2 receptor stimulation. Am J Respir Crit Care Med. 1997 Aug;156(2 Pt 1):438-44. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.3181 mL	16.5904 mL	33.1807 mL	82.9518 mL
	5 mM	0.6636 mL	3.3181 mL	6.6361 mL	16.5904 mL
	10 mM	0.3318 mL	1.6590 mL	3.3181 mL	8.2952 mL
	15 mM	0.2212 mL	1.1060 mL	2.2120 mL	5.5301 mL
	20 mM	0.1659 mL	0.8295 mL	1.6590 mL	4.1476 mL
	25 mM	0.1327 mL	0.6636 mL	1.3272 mL	3.3181 mL
	30 mM	0.1106 mL	0.5530 mL	1.1060 mL	2.7651 mL
	40 mM	0.0830 mL	0.4148 mL	0.8295 mL	2.0738 mL
	50 mM	0.0664 mL	0.3318 mL	0.6636 mL	1.6590 mL
	60 mM	0.0553 mL	0.2765 mL	0.5530 mL	1.3825 mL
	80 mM	0.0415 mL	0.2074 mL	0.4148 mL	1.0369 mL
	100 mM	0.0332 mL	0.1659 mL	0.3318 mL	0.8295 mL

Keywords

Dobutamine

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Dobutamine

GPCR/G Protein Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Anti-Obesity Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Antidepressant Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Pain-Related Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Activators Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Dobutamine

Alle Adrenergic Receptor Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Dobutamine Related Classifications

HY-15746A Related Classifications